- Home
- SOUN vs SLS Comparison
SOUN vs SLS Comparison
Compare SOUN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOUN | SLS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SOUN | SLS |
|---|---|---|
| Price | $4.52 | $11.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $12.57 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 12.2M | 4.9M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.02 | N/A |
| Revenue Next Year | $55.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.39 | $1.39 |
| 52 Week High | $19.09 | $15.88 |
Technical Indicators
Market Signals| Indicator | SOUN | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 46.76 |
| Support Level | $4.39 | $10.78 |
| Resistance Level | $6.18 | $12.62 |
| Average True Range (ATR) | 0.24 | 0.85 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 7.55 | 50.28 |
Price Performance
Historical ComparisonAbout SOUN SoundHound AI Inc
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.